Clinical Trials Logo

Midgut Neuroendocrine Tumours clinical trials

View clinical trials related to Midgut Neuroendocrine Tumours.

Filter by:
  • None
  • Page 1

NCT ID: NCT02651987 Completed - Clinical trials for Midgut Neuroendocrine Tumours

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

CLARINET FORTE
Start date: December 15, 2015
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

NCT ID: NCT02358356 Completed - Clinical trials for Midgut Neuroendocrine Tumours

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

CONTROL NETS
Start date: November 2015
Phase: Phase 2
Study type: Interventional

Two parallel phase II randomized open label trials of Lutetium-177 Octreotate (177Lu-Octreotate) peptide receptor radionuclide therapy (PRRT) and capecitabine (CAP)/temozolomide (TEM) chemotherapy (chemo): (i) versus CAPTEM alone in the treatment of low to intermediate grade pancreatic neuroendocrine tumours (pNETs); (ii) versus PRRT alone in the treatment of low to intermediate grade mid gut neuroendocrine tumours (mNETs).